CAS: 20804-76-6 - 3-hydroxy-4-(1-naphthyloxy)butyronitrile
Fórmula:C14H13NO2
InChI:InChI=1S/C14H13NO2/c15-9-8-12(16)10-17-14-7-3-5-11-4-1-2-6-13(11)14/h1-7,12,16H,8,10H2
Clave InChI:InChIKey=ASZJWZSLVVSBAH-UHFFFAOYSA-N
SMILES:N#CCC(O)COC1=CC=CC=2C=CC=CC12
- Sinónimos:
- 3-Hydroxy-4-(1-naphthalenyloxy)butanenitrile
- 3-Hydroxy-4-(1-naphthyloxy)-butanenitrile
- 3-Hydroxy-4-(Naphthalen-1-Yloxy)Butanenitrile
- Butanenitrile, 3-hydroxy-4-(1-naphthalenyloxy)-
- Butyronitrile, 3-hydroxy-4-(1-naphthyloxy)-
| Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
|---|---|---|---|---|
 | Butanenitrile, 3-hydroxy-4-(1-naphthalenyloxy)- REF: IN-DA002JGBCAS: 20804-76-6 | - - - | A consultar | Mar 10 Dic 24 |
 | 3-Hydroxy-4-(1-naphthyloxy)-butanenitrile REF: TR-H951065CAS: 20804-76-6 | - - - | 118,00 €~324,00 € | Vie 27 Dic 24 |
 | 3-Hydroxy-4-(1-naphthyloxy)-butanenitrile REF: 3D-VAA80476CAS: 20804-76-6 | Min. 95% | A consultar | Vie 17 Ene 25 |
Butanenitrile, 3-hydroxy-4-(1-naphthalenyloxy)-
CAS:20804-76-6
Fórmula:
C14H13NO2
Forma y color:
Solid
Peso molecular:
227.2585
Ref: IN-DA002JGB
| Tamaño no definido | A consultar |
Entrega estimada en Estados Unidos, el Martes 10 de Diciembre de 2024
3-Hydroxy-4-(1-naphthyloxy)-butanenitrile
Producto controladoCAS:20804-76-6
Applications 3-Hydroxy-4-(1-naphthyloxy)-butanenitrile is an intermediate in the synthesis of Nadoxolol (N201040), which is a beta-adrenergic …
Fórmula:
C14H13NO2
Forma y color:
Neat
Peso molecular:
227.26
Ref: TR-H951065
| 25mg | 118,00 € | ||
| 50mg | 188,00 € | ||
| 100mg | 324,00 € |
Entrega estimada en Estados Unidos, el Viernes 27 de Diciembre de 2024
3-Hydroxy-4-(1-naphthyloxy)-butanenitrile
CAS:20804-76-6
Please enquire for more information about 3-Hydroxy-4-(1-naphthyloxy)-butanenitrile including the price, delivery time and more detailed …
Fórmula:
C14H13NO2
Pureza:
Min. 95%
Peso molecular:
227.26 g/mol
Ref: 3D-VAA80476
| 100mg | A consultar | ||
| 250mg | A consultar |
Entrega estimada en Estados Unidos, el Viernes 17 de Enero de 2025
